INHIBITION OF WNT, TGF BETA AND HIPPO SIGNALING PATHWAYS TO TREAT CANCER, ORGAN FIBROSIS AND METABOLIC DISORDERS

摘要

Compounds, or pharmaceutically acceptable salts or esters thereof, having a structure of: wherein each of R¹-R⁵ is individually selected from H, halogen, optionally substituted alkyl, optionally substituted alkoxy, nitro, sulfonamide, hydroxy, or amino; and R⁶ is selected from H, optionally substituted alkyl, or optionally substituted aryl.;